Table 3 Mean difference between-group at 2, 6 and 12 months follow up (Adjusted analysis by GEE model)

From: The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis; a one year randomized clinical trial

  Test of Between-group (mean change from reference group)
PRGF vs PRP HA vs PRP Ozone vs PRP HA vs PRGF Ozone vs PRGF Ozone vs HA
Outcomes MDa (95%CI) MDa (95%CI) MDa (95%CI) MDa (95% CI) MDa (95% CI) MDa (95% CI)
WOMAC
Pain T2 − 0.03(− 0.67,0.60) 0.46(− 0.18,1.10) − 1.2(− 1.8,-0.54)*** 0.49(− 0.15,1.14) − 1.15(− 1.80,-0.50)*** −1.65(− 2.30,-0.99)***
 T6 −0.01(− 0.65,0.62) 0.97 (0.32,1.61)** 1.70 (1.05,2.35)*** 0.98 (0.33,1.63)** 1.71 (1.06,2.37)*** 0.73 (0.07,1.38)*
 T12 0.03(−0.60,0.66) 1.29 (0.65,1.94)*** 2.69 (2.04,3.33)*** 1.26 (0.62,1.91)*** 2.66 (2.0,3.31)*** 1.39 (0.73,2.04)***
Stiff T2 0.09(− 0.32,0.50) −0.20(− 0.62,0.21) 0.11(− 0.30,0.54) − 0.29(− 0.72,0.12) 0.02(− 0.40,0.45) 0.32 (− 0.10,0.75)
 T6 0.06(− 0.34,0.48) −0.01(− 0.43,0.40) 0.74 (0.32,1.17)*** −0.08(− 0.50,0.34) 0.67 (0.25,1.10)** 0.75 (0.32,1.18)***
 T12 − 1.0(− 1.3,-0.7) − 0.96(− 1.3,-0.6) −0.8(− 1.1,-0.6)*** 0.08(− 0.34,0.50) 0.77 (0.34,1.19)*** 0.69 (0.25,1.12)**
Fun T2 0.09(− 0.32,0.50) −0.20(− 0.62,0.21) 0.11(− 0.30,0.53) −0.06(− 2.11,1.99) −4.44(− 6.51,-2.38)*** −4.38(− 6.47,-2.30)***
 T6 0.07(− 0.34,0.40) − 0.01(− 0.43,0.40) 0.74 (0.32,1.17)*** 2.32 (0.26,4.37)* 5.13 (3.07,7.20)*** 2.81 (0.73,4.90)**
 T12 0.04(− 0.37,0.45) 0.12(− 0.29,0.54) 0.81 (0.38,1.23)*** 4.73 (2.67,6.78)*** 6.09 (4.02,8.15)*** 1.35(− 0.72,3.44)
Total T2 − 0.31(− 2.94,2.30) 0.88(− 1.76,3.53) − 5.89(− 8.56,-3.23)*** 1.20(− 1.46,3.86) − 5.5(− 8.25,-2.90)*** −6.77(− 9.48,-4.07)***
 T6 −0.41(− 3.03,2.20) 4.30 (1.65,6.95)*** 7.12 (4.46,9.78)*** 4.71 (2.05,7.37)*** 7.53 (4.86,10.21)*** 2.81 (0.11,5.52)*
 T12 −0.40(−3.02,2.21) 7.09 (4.44,9.73)*** 9.12 (6.46,11.78)*** 7.49 (4.83,10.15)*** 9.52 (6.85,12.20)*** 2.03(− 0.66,4.73)
LEQ
Pain T2 0.05(− 0.39,0.50) − 0.55(− 1.0,-0.09)* − 1.15(− 1.61,-0.69)*** −0.60(− 1.06,-0.14)** −1.20(− 1.66,-0.74)*** −0.60(− 1.06,-0.13)*
 T6 0.06(− 0.38,0.51) 0.15(− 0.29,0.61) 0.39(− 0.06,0.85) 0.09(− 0.36,0.55) 0.33(− 0.12,0.78) 0.23(− 0.22,0.70)
 T12 0.09(− 0.36,0.53) 0.44(− 0.01,0.89) 0.96 (0.50,1.41)*** 0.35(− 0.10,0.80) 0.87 (0.41,1.33)*** 0.52 (0.06,0.98)
Walk T2 0.03 (− 0.2,0.26) − 0.04(− 0.28,0.18) 0.15(− 0.09,0.38) − 0.07(− 0.31,0.15) 0.11(− 0.11,0.35) 0.19(− 0.02,0.43)
 T6 −0.01(− 0.23,0.22) − 0.04(− 0.27,0.19) 0.20(− 0.03,0.43) − 0.03(− 0.27,0.20) 0.20(− 0.03,0.44) 0.24 (0.01,0.48)*
 T12 0.07(− 0.15,0.30) 0.08(− 0.14,0.32) 0.18(− 0.04,0.42) 0.01(− 0.22,0.24) 0.11(− 0.12,0.35) 0.10(− 0.14,0.34)
ADL T2 0.11(− 0.22,0.44) − 0.01(− 0.34,0.32) −0.29(− 0.62,0.04) −0.12(− 0.45,0.21) −0.40(− 0.73,-0.06)* −0.27(− 0.61,0.06)
 T6 0.03(− 0.29,0.36) 0.80 (0.46,1.13)*** 1.02 (0.68,1.36)*** 0.76 (0.43,1.10)*** 0.98 (0.65,1.32)*** 0.22(−0.12,0.56)
 T12 0.05(−0.27,0.38) 0.65 (0.32,0.99)*** 0.78 (0.44,1.11)*** 0.59 (0.26,0.93)*** 0.72 (0.38,1.06)*** 0.12(−0.21,0.46)
Total T2 0.12(−0.59,0.84) − 0.24(− 0.97,0.47) − 1.29(− 2.02,-0.56)*** −0.36(− 1.09,0.35) −1.42(− 2.15,-0.68)*** −1.05(− 1.79,-0.31)**
 T6 0.07(− 0.64,0.78) 1.37 (0.65,2.10)*** 1.61 (0.88,2.34)*** 1.30 (0.57,2.03)*** 1.54 (0.81,2.27)*** 0.24(− 0.49,0.98)
 T12 0.25(− 0.45,0.97) 1.63 (0.90,2.35)*** 1.93 (1.20,2.65)*** 1.37 (0.64,2.10)*** 1.67 (0.93,2.40)*** 0.29(−0.44,1.03)
VAS (1–10)
 T2 0.05 (−0.45,0.56) −0.05 (− 0.56,0.45) −0.72 (−1.24,-0.24)** −0.11(− 0.62,0.40) −0.78(− 1.30,-0.26)** −0.67 (− 1.2,-0.14)
 T6 0.04(− 0.46,0.55) 0.31(− 0.20,0.82) 0.57 (0.06,1.09) 8 −.26(− 0.25,0.77) 0.52 (0.01,1.04)* 0.26(− 0.25,0.78)
 T12 −0.02(− 0.53,0.48) 0.75 (0.23,1.26)** 2.05 (1.53,2.56)*** 0.77 (0.26,1.29)** 2.07 (1.56,2.59)*** 1.29 (0.77,1.82)***
  1. Abbreviations: SD standard deviation; PRGF plasma rich in growth factor; PRP platelet-rich plasma; HA hyaluronic acid; VAS visual analog scale; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index; LEQ Lequesne Index; MD mean difference; CI confidences interval; T2 2nd month post injection, T6 6th month post injection, T12 12th month post injection
  2. * Between-group effects p < 0.05; ** Between-group p < 0.01; *** Between-group p < 0.001
  3. a Adusted generalized estimating equations model after controlling the baseline Outcome, sex, age, BMI;